Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Eastwood Bio-Medical Canada Inc. (V:EBM)

Business Focus: Alternative Medicine

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEDAR
Company Contact
Address: 1130 - 4871 Shell Road
Tel: N/A
IR: See website
Key People
Yunji Kim
President, Chief Financial Officer, Corporate Secretary, Director
Youngsoo Kim
Chief Executive Officer, Director
Business Overview
Eastwood Bio-Medical Canada Inc. (EMBC) is a natural health supplement distribution company. The Company is engaged in the marketing and distributing natural health products in North America. It is a distributor of the Eleotin line of products, which include formulations based on natural ingredients. The Eleotin products include natural remedies for certain metabolic disorders, such as blood glucose disorders, hypertension and obesity. The Company's licensed products include Eleotin A 700, which is a treatment for spleen deficiency, lack of appetite and fatigue; Eleotin AL88, a laxative; Eleotin Cal20, for bone and teeth maintenance; Eleotin V3D for the development and maintenance of bones and teeth; Eleotin G2000 for cardiovascular health; Eleotin H55, a sedative and tension relief, Eleotin Zn330, which is involved in tissue formation and metabolism; Eleotin Bentley, which is used to promote healthy glucose levels, and Eleotin LBM, which is recommended for hypertension relief.
Financial Overview
For the nine months ended 31 July 2021, EastwoodBio-Medical Canada Inc revenues increased 38% to C$710K.Net loss applicable to common stockholders increased 4% toC$598K. Revenues reflect Asia segment increase of 68% toC$421K, Canada segment increase of 19% to C$153K. Highernet loss reflects Management Fees increase of 48% to C$182K(expense), Wages and Salaries increase of 15% to C$375K(expense).
Reporting Currency: Canadian Dollars
Enterprise value: $100.59M as of Jul 31, 2021
Annual revenue (TTM): $0.91M as of Jul 31, 2021
EBITDA (TTM): -$0.87M as of Jul 31, 2021
Net annual income (TTM): -$0.87M as of Jul 31, 2021
Free cash flow (TTM): -$0.01M as of Jul 31, 2021
Net Debt Last Fiscal Year: N/A
Shares outstanding: 68,885,969 as of Jul 31, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization